Kowa Pharms Drug Patent Portfolio
Kowa Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Kowa Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs | 03 Jun, 2031 | Active |
| US10238668 | Co-crystals of tramadol and coxibis | 19 Apr, 2030 | Active |
| US10245276 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US10548909 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US11478488 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US8598152 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US9012440 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
Latest Legal Activities on Kowa Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kowa Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US9012440 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8846744 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10548909 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8598152 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10238668 |
| Notice of Final Determination- Ineligible | 06 Jun, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10548909 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US9012440 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8598152 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8846744 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10238668 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2023 | US10548909 |
| Initial letter Re: PTE Application to regulating agency | 28 Feb, 2023 | US10245276 |
| Initial letter Re: PTE Application to regulating agency | 28 Feb, 2023 | US10548909 |
Kowa Pharms's Family Patents
Kowa Pharms drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 13.1% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Kowa Pharms Drug List
Given below is the complete list of Kowa Pharms's drugs and the patents protecting them.
1. Seglentis
Seglentis is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
03 Jun, 2031
(6 years from now)
| Active |
| US10238668 | Co-crystals of tramadol and coxibis |
19 Apr, 2030
(4 years from now)
| Active |
| US10245276 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US10548909 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US11478488 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US8598152 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US9012440 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seglentis's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List